Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

[News]

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

More... (http://www.news-medical.net/news/20120830/Sicor-Biotech-receives-FDA-approval-for-tbo-filgrastim-to-treat-severe-neutropenia.aspx)